Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
Paclitaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors
- Conditions
- First Posted Date
- 2004-03-15
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 18
- Registration Number
- NCT00004863
- Locations
- 🇺🇸
Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States
Paclitaxel in Treating Patients With Recurrent or Progressive Advanced Ovarian Cancer
- Conditions
- First Posted Date
- 2004-03-12
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00002928
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
- Conditions
- Ovarian Endometrioid AdenocarcinomaOvarian Mixed Epithelial CarcinomaPrimary Peritoneal Cavity CancerStage II Ovarian Epithelial CancerStage III Ovarian Epithelial CancerFallopian Tube CancerBrenner TumorOvarian Clear Cell CystadenocarcinomaOvarian Mucinous CystadenocarcinomaOvarian Serous Cystadenocarcinoma
- Interventions
- First Posted Date
- 2004-03-10
- Last Posted Date
- 2019-07-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 113
- Registration Number
- NCT00079430
- Locations
- 🇯🇵
Kawasaki Medical School, Okayama-Ken, Kurashiki, Japan
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-03-10
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- Japan Multinational Trial Organization
- Registration Number
- NCT00079287
- Locations
- 🇯🇵
Nagoya University Hospital, Aichi, Japan
🇯🇵Asahikawa Medical College, Asahikawa, Japan
🇯🇵National Hospital Organization - Ehime National Hospital, Ehime, Japan
Paclitaxel and BMS-214662 in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2004-03-08
- Last Posted Date
- 2010-06-11
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT00006018
- Locations
- 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Cleveland, Ohio, United States
🇺🇸Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer
- Conditions
- First Posted Date
- 2004-02-27
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Matrix Pharmaceutical
- Registration Number
- NCT00022217
- Locations
- 🇺🇸
Veterans Affairs Medical Center - Tucson, Tucson, Arizona, United States
🇺🇸Division of Head and Neck Surgery, Evanston, Illinois, United States
🇺🇸Louisiana State University Health Sciences Center - Shreveport, Shreveport, Louisiana, United States
Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2004-02-27
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT00021372
- Locations
- 🇺🇸
Kimball Medical Center, Lakewood, New Jersey, United States
🇺🇸Delaware County Memorial Hospital, Drexel Hill, Pennsylvania, United States
🇺🇸Community Medical Center, Toms River, New Jersey, United States
Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer
- Conditions
- First Posted Date
- 2004-02-27
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- Cytran
- Registration Number
- NCT00017303
- Locations
- 🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
🇺🇸University of Kansas School of Medicine-Wichita, Wichita, Kansas, United States
🇺🇸Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
Capecitabine, Paclitaxel, and Trastuzumab in Treating Patients With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2004-02-26
- Last Posted Date
- 2012-02-07
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Registration Number
- NCT00006108
- Locations
- 🇺🇸
Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States
Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-02-26
- Last Posted Date
- 2020-08-18
- Lead Sponsor
- Medstar Health Research Institute
- Target Recruit Count
- 4
- Registration Number
- NCT00006472
- Locations
- 🇺🇸
Union Memorial Hospital, Baltimore, Maryland, United States
🇺🇸Harbor Hospital Center, Baltimore, Maryland, United States
🇺🇸Franklin Square Hospital Center, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.